Medicine (의예과)3,518
-
1
Article
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
고수진
;
고윤호
;
구동회
;
et al
2021
-
2
Article
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
이재련
;
Boris Yakovlevich Alekseev
;
Charles Schloss
;
et al
2021
-
3
Article
Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5
김좌훈
;
김형돈
;
박인근
;
et al
2021
-
4
Article
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial
이재련
;
Andrea Necchi
;
Arjun V Balar
;
et al
2021
-
5
Article
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration
이재련
;
Ajjai Alva
;
Andrea Gallina
;
et al
2021
-
6
Article
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
이재련
;
Alexandra Drakaki
;
Archana Agarwal
;
et al
2021
-
7
Article
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study
이재련
;
Chung-Hsin Chen
;
Daqing Zhou
;
et al
2021
-
8
Article
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC
김영석
;
이용준
;
이재련
;
et al
2021
-
9
Article
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
김미소
;
김범석
;
박권오
;
et al
2021
-
10
Article
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
이재련
;
Christof Vulsteke
;
Chunzhang Wu
;
et al
2021
-
11
Article
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
2021
-
12
Article
2020 Korean guidelines for the management of metastatic prostate cancer
강병욱
;
강지훈
;
김달용
;
et al
2021
-
13
Article
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
이재련
;
Aaron Hansen
;
Aly-Khan A Lalani
;
et al
2021
-
14
Article
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
이재련
;
Aaron Hansen
;
Anna Fraccon
;
et al
2021
-
15
Article
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer A Randomized Clinical Trial
이대호
;
Alberto A Chiappori
;
Chris Liang
;
et al
2021
-
16
Article
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC : Initial Results of the Phase 2 ALK-Positive Cohort
이대호
;
Daniel S W Tan
;
David S Shames
;
et al
2021
-
17
Article
Meta-analysis of transanal versus laparoscopic total mesorectal excision for rectal cancer: a 'New Health Technology'assessment in South Korea
이대호
;
Chang Soo Eun
;
Jeong-Heum Baek
;
et al
2021
-
18
Article
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
이대호
;
Adrian Langleben
;
Ayman Samkari
;
et al
2021
-
19
Article
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
이대호
;
Adnan Nagrial
;
Byoung Chul Cho
;
et al
2021
-
20
Article
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
이대호
;
Aaron S Mansfield
;
Benjamin Besse
;
et al
2021